Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02557243|
Recruitment Status : Recruiting
First Posted : September 23, 2015
Last Update Posted : January 11, 2019
|Condition or disease|
|Soft Tissue Neoplasms Bone Neoplasms|
Sarcomas are a heterogeneous group of rare tumors that arise predominantly from the embryonic mesoderm. The various sarcomas include bone sarcomas (osteosarcomas and chondrosarcomas), Ewing's sarcomas, peripheral primitive neuroectodermal tumors, and soft tissue sarcomas.
Soft tissue sarcomas account for approximately 1% of adult malignancies and 7% to 15% of pediatric malignancies. Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood.
There is some confusion within segments of the medical community as to the precise meaning of "soft tissue." The soft tissue of the human body includes all extraskeletal tissue that is neither epithelial, hematopoietic (marrow derived blood elements), nor parenchymal (constituent of a visceral organ). The nervous system is divided such that neither the glial nor the central neuronal elements are considered to be soft tissue, though by convention the peripheral nervous system is. In sum, the soft tissues consist of adipose tissue, fibrous tissue, musculature, vascular structures, and peripheral nerves.
About 50% to 60% of sarcomas occur in the extremities, and although they are rare, they are responsible for more deaths than testicular cancer, Hodgkin's disease, and thyroid cancer combined.
Patients & Methods:
From January 2000 till December 2015, retrieval & analysis of the medical records of pediatric patients with soft tissue & bone tumors involving the extremities will be made at the pediatric oncology department, South Egypt Cancer Institute which represents the largest referral center in Upper Egypt. These data will be categorized according to demographic characteristics, clinico-pathologic features, treatment modalities received, and outcomes of treatments in these patients.
|Study Type :||Observational|
|Estimated Enrollment :||260 participants|
|Official Title:||Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||November 2019|
|Estimated Study Completion Date :||December 2019|
- Overall survival (OS) [ Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years ]Time from the date of initiation of treatment until death from any cause
- Event Free Survival (EFS) [ Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years ]Time from the date of initiation of treatment until disease progression, or death for any reason.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02557243
|Assiut, Egypt, 71515|
|Contact: Ahmed M. Morsy, MD +2 01003314522 firstname.lastname@example.org|
|Principal Investigator: Ahmed M. Morsy, MD|
|Principal Investigator: Khalid M. Rezk, MD|
|Principal Investigator: Badawy M. Ahmed, MD|
|Principal Investigator: Ameer M. Abuelgheet, MD|
|Principal Investigator: Marwa I. Abdelgawad, MD|